ACE2 and COVID-19: Besides the application of specific anti-SARS-CoV-2, the use of anti-ACE2 with anti-FcγRII monoclonal antibodies to block ADE activation and plasmapheresis for restraining cytokine storm elements in plasma has also been proposed as potentially the most effective method of COVID-19 treatment [127].